Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
Tel: 86-21-58550039;86-21-31268550-8004
Mobile:
Tel: 86-21-58550039;86-21-31268550-8004
Fax: 86-21-50790419
Province/state: shanghai
City: shanghai
Street: Suite B-10#, 6999 Chuansha Road, Pudong District, Shanghai 201202, China
MaxCard:
CAS NO.74397-12-9
Factory Supply High Purity 74397-12-9 with Lowest Price
Limaprost, an alprostadil (prostaglandin E1) analogue, is a vasodilator that increases blood flow and inhibits platelet aggregation. The efficacy of oral limaprost was evaluated in adult Japanese patients in three randomised, double-blind, 6-week trials. One study included patients with thromboangiitis obliterans and two trials included patients with lumbar spinal canal stenosis. Limaprost was generally well tolerated and serious adverse events were uncommon. THROMBOANGIITIS OBLITERANS: In a randomised, double-blind trial in Japanese patients primarily with thromboangiitis obliterans (n=136), there was no significant difference between patients receiving limaprost 30 microg/day and those receiving oral ticlopidine 500 microg/day in the improvement of ischaemic symptoms. LUMBAR SPINAL CANAL STENOSIS: Limaprost 15 microg/day was superior to limaprost 3 microg/day for overall drug usefulness and overall improvement from baseline to study end in a phase III trial in 146 patients with lumbar spinal canal stenosis. Assessment of overall improvement considered various objective symptoms (e.g. muscle strength, walking ability) and subjective symptoms (e.g. pain or numbness in extremities), while overall usefulness also considered safety issues. The efficacy of limaprost 15 microg/day was not significantly different from that of 30 microg/day, but tended to be better than that of 6 microg/day in a phase II trial in patients with lumbar spinal canal stenosis and normal straight leg raise test results. The optimal dosage of limaprost for this indication was therefore deemed to be 15 microg/day.
Hormones and related drugs; Prostaglandins;It can improve the peripheral circulation, inhibit the content of cyclic phosphate in platelets and the production of thromboxane. It is used for occlusive thrombovasculitis and ischemic symptoms such as ulcer, pain and cold sensation.
Chemvon Biotechnology Co. Ltd is a high-technology pharmaceutical and fine chemical company, which is speciallized in RD, manufacturing and sales of APIs (Active Pharmaceutical Ingredients) and some organic intermediates. With the experience and specialization in technology of asymmetric synthesis, total synthesis of natural products, organometallic reactions, chromatographic chiral separation, we supply high quality products of APIs, intermediates, speciality chemicals. and our contract services including research manufacture and custom synthesis from laboratory to commercial production are also offered on a confidential basis.
Limaprost is an analog of PGE1 with structural modifications intended to give a prolonged half-life and greater potency. It is orally active in both guinea pigs and rats at doses of 100 μg/kg as an inhibitor of ADP and collagen induced platelet aggregation. It is 10-1,000 times more potent than PGE1 as a platelet adhesive inhibitor, measured in vitro. Intra-coronary injection (100 ng/kg) or intravenous injection (3 μg/kg) in anesthetized dogs causes vasodilation and increased coronary blood flow by 60-80%. Significant hypotensive effects were seen at 100 and 300 μg/kg orally in rats.
Name
Limaprost
ONO 1206
C22H36O5
380.52
74397-12-9
98% min
HNMR/IR